<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981951</url>
  </required_header>
  <id_info>
    <org_study_id>F.Med.25th August/2020/10</org_study_id>
    <nct_id>NCT04981951</nct_id>
  </id_info>
  <brief_title>Th Effects of a Drug Dexmedotemidine in Regional Anesthesia in Participants Undergoing Upper Limb Surgeries</brief_title>
  <official_title>Dexmedetomidine as an Adjuvant to Local Anesthesia in Supraclavicular Plexus Block, A Randomized Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zaher Nazzal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>An-Najah National University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will assess the effect of combined Dexmedetomidine and Bupivacaine&#xD;
      analgesia on the onset and duration of anesthesia in supraclavicular plexus block compared to&#xD;
      Bupivacaine alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who fulfill the inclusion criteria will be enrolled in this study to achieve&#xD;
      sample size of 140 participants, 70 participants in each group.&#xD;
&#xD;
      Participants were blindly randomized into two groups: group A (Bupivacaine alone) and group B&#xD;
      (Bupivacaine with Dexmedetomidine).&#xD;
&#xD;
      On the morning of the surgery day, and before performing the procedure on the targeted hand,&#xD;
      a venous cannula 18gauze was secured on the opposite hand. Routine monitors like pulse&#xD;
      oximetry, non-invasive blood pressure, and electrocardiogram were attached during the&#xD;
      procedure.&#xD;
&#xD;
      Study medications were prepared for each group, which is Bupivacaine (30ml) only for group A&#xD;
      and Bupivacaine (30 ml) with Dexmedetomidine (1 mcg /kg) for group B. Then, SCPB was done&#xD;
      under ultrasound guidance which increases the safety due to improved monitoring of anatomy&#xD;
      and needle placement. A needle was placed within the brachial plexus sheath posterior to the&#xD;
      subclavian artery, and the local anesthetic injected to surround the trunks and divisions of&#xD;
      the brachial plexus at this level.&#xD;
&#xD;
      Patients were evaluated for the onset of the sensory and motor block every 3 minutes after&#xD;
      completion of injection till their onset, and, at 15, 30, 45, 60, 90, and 120 min; and then&#xD;
      hourly (even after surgery), until they had resolved.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The onset of anaesthesia in supraclavicular plexus block</measure>
    <time_frame>&quot;up to 9 hours&quot;</time_frame>
    <description>Sensory block assessed by pinprick test with a blunt 25-G hypodermic needle. Grade 0: sharp pin sensation felt, grade 1: analgesia, dull sensation felt, grade 2: anesthesia, no sensation felt the onset of sensory block is the interval between the end of total local anesthetic administration and sensory block grade 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The duration of anesthesia in supraclavicular plexus block</measure>
    <time_frame>&quot;up to 9 hours&quot;</time_frame>
    <description>The motor blockade assessed using the Modified Bromage scale (MBS). Grade 0: able to raise the extended arm to 90 degrees for 2 seconds; grade 1: able to bend the elbow and move the fingers but not the extended arm; grade 2: unable to flex the elbow but able to move the fingers; grade 3: unable to move the arm, elbow, and fingers. The onset of the motor blockade is the interval from injection of the local anesthetic to motor analysis equivalent to Bromage score 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative heart rate</measure>
    <time_frame>&quot;1 hour&quot;</time_frame>
    <description>Heart rate per min is assessed intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood pressure as mm Hg</measure>
    <time_frame>&quot;1 hour&quot;</time_frame>
    <description>Blood pressure assessed by a non-invasive monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative somnolence</measure>
    <time_frame>&quot;1 hour&quot;</time_frame>
    <description>Somnolence assessed using Ramsay Sedation Scale. It grades somnolence on a scale of 1-6: 1 = anxious, agitated, restless; 2 = cooperative, oriented, tranquil; 3 = responds to commands only; 4 = brisk response to light glabellar tap or loud noise; 5 = sluggish response to light glabellar tap or loud noise; 6 = no response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative heart rate</measure>
    <time_frame>&quot;up to 6 hours&quot;</time_frame>
    <description>Heart rate per min is assessed postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative blood pressure</measure>
    <time_frame>&quot;up to 6 hours&quot;</time_frame>
    <description>Blood pressure assessed by a non-invasive monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative somnolence</measure>
    <time_frame>&quot;up to 6 hours&quot;</time_frame>
    <description>Somnolence assessed using Ramsay Sedation Scale. It grades somnolence on a scale of 1-6: 1 = anxious, agitated, restless; 2 = cooperative, oriented, tranquil; 3 = responds to commands only; 4 = brisk response to light glabellar tap or loud noise; 5 = sluggish response to light glabellar tap or loud noise; 6 = no response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postoperative nausea and vomiting.</measure>
    <time_frame>&quot;up to 6 hours&quot;</time_frame>
    <description>Vomiting assessed by mentoring the patients actively. Nausea assessed by asking the patients directly.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Supraclavicular Brachial Plexus Block</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine and Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given Dexemtomidine ( the intervention) added to the Bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will be given Bupivacaine alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Highly selective Î±2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.</description>
    <arm_group_label>Dexmedetomidine and Bupivacaine</arm_group_label>
    <other_name>non</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18-75 years.&#xD;
&#xD;
          -  Classified as grades 1 or 2 by the American Society of Anesthesiology Classification&#xD;
             of .physical status.&#xD;
&#xD;
          -  Willing and able to sign a consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the following conditions will be excluded: Known hypersensitivity to&#xD;
             Bupivacaine, Dexmedetomidine, and local anesthetics.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Peripheral neuropathy.&#xD;
&#xD;
          -  SevereCoagulopathy.&#xD;
&#xD;
          -  Infection at the site of block.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Cardiac arrhythmias.&#xD;
&#xD;
          -  Prescription of beta blockers.&#xD;
&#xD;
          -  Psychological disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaher Nazzal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>An-Najah National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wael Sadaqa, MD</last_name>
    <role>Study Director</role>
    <affiliation>An-Najah National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zaher Nazzal, MD</last_name>
    <phone>(+970) 9 2345113</phone>
    <email>znazzal@najah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zaher Nazzal</name>
      <address>
        <city>Nablus</city>
        <state>Wes-Bank</state>
        <zip>7704</zip>
        <country>Palestinian Territory, occupied</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wael Sadaqa, MD</last_name>
      <phone>+970 599 782 246</phone>
      <email>w.sadaqa@najah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zaher Nazzal, MD</last_name>
      <phone>+970 599 545 421</phone>
      <email>znazzal@najah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Palestinian Territory, occupied</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>An-Najah National University</investigator_affiliation>
    <investigator_full_name>Zaher Nazzal</investigator_full_name>
    <investigator_title>Head of Research Unit</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Randomized Controlled Trial.</keyword>
  <keyword>Supraclavicular Plexus Block</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>Palestine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

